VistaGen Therapeutics (VTGN) investor relations material

Executive summary

• Focused on late-stage clinical development of intranasal pherine product candidates for neuropsychiatric and women's health disorders, with fasedienol as the lead candidate for social anxiety disorder (SAD).

• Preliminary data from PALISADE-3 and PALISADE-4 studies showed nominally significant efficacy signals in very severe social anxiety subgroups, with favorable safety and tolerability.

• FDA engagement planned for potential Phase 3 path forward for fasedienol.

• Ongoing cash preservation measures, including workforce reduction, following negative trial results and to extend operational runway.

• Leadership strengthened with appointments of a new Chief Medical Officer and Board member with neuroscience expertise.

Financial highlights

• Net loss for the quarter ended June 30, 2026 was $13.0 million, compared to $15.1 million for the same quarter last year.

• Total revenues were $1.5 million, up from $0.2 million year-over-year, primarily due to $1.3 million recognized under the Fuji Pharma Negotiation Agreement.

• Research and development expenses decreased to $10.9 million from $11.7 million year-over-year, reflecting reduced clinical activity and cash preservation.

• General and administrative expense was $3.9 million, down from $4.4 million year-over-year.

• Cash, cash equivalents, and marketable securities totaled $31.7 million as of June 30, 2026.

Outlook and guidance

• Substantial doubt exists about the ability to continue as a going concern beyond twelve months from the financial statement issuance date without additional capital.

• Cash runway expected to fund operations into 2027, but not for more than a year from the reporting date.

• Future revenue expected to decrease absent new milestone achievements or agreements.

• Research and development expenses projected to decline further as current trials conclude and cash preservation continues.

• G&A expenses expected to remain stable, contingent on regulatory developments.